Preprint
Line immunoassay for confirmation and discrimination of human T-cell lymphotropic virus infections in inconclusive western blot serum samples from Brazil
Registro en:
CAMPOS, Karoline Rodrigues et al. Line immunoassay for confirmation and discrimination of human T-cell lymphotropic virus infections in inconclusive western blot serum samples from Brazil. Journal of Clinical Microbiology, p. 1-35, Nov. 2019.
0095-1137
10.1128/JCM.01384-19
Autor
Campos, Karoline Rodrigues
Santos, Fred Luciano Neves
Brito, Vanessa da Silva
Gonçalves, Noilson Lazaro Sousa
Araujo, Thessika Hialla Almeida
Castro Filho, Bernardo Galvão
Araujo, Adele Caterino
Resumen
Coordenação de
363 Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Fundação de Amparo à
364 Pesquisa do Estado de São Paulo (FAPESP; 2012/51220-8 and 2016/03654-0), and
365 Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; 302661/2015-
366 8). In Salvador by grants of: (CNPq; 473667/2012 and 311054/2014-50), Fundação de
367 Amparo à Pesquisa do Estado da Bahia (FAPESB; 2574/2013), and Fundação Nacional
368 para o desenvolvimento do Ensino Superior (FUNDADESP; 9600113). Difficulties to confirm and discriminate human T-cell lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2) infections by serological Western Blotting (WB) assay (HTLV Blot 2.4, MP Biomedicals) has been reported in Brazil, mainly in HIV/AIDS patients, with a large number of WB-indeterminate and WB-positive but HTLV untypeable results. Nonetheless, the line immunoassay (LIA) (INNO-LIA HTLV-I/II, Fujirebio) was pointed to enhance specificity and sensitivity for confirming HTLV-1/2 infections. To add information concerning the improved ability of LIA in relation to WB when applied in samples of individuals from different risk-groups from Brazil, we performed the present study. Three groups were analyzed: group 1 [G1], 62 samples from HIV/AIDS patients from São Paulo-SP (48 WB-indeterminate + 14 HTLV); group 2 [G2], 24 samples from patients with hepatitis B or hepatitis C from São Paulo (21 WB-indeterminate + 3 HTLV; 17 HIV-seropositive), and group 3 [G3], 25 samples from HTLV out-patients clinic from Salvador-Bahia (16 WB-indeterminate + 9 HTLV; all HIV-seronegative). Overall, the LIA confirmed HTLV-1/2 infection (HTLV-1, HTLV-2 or HTLV) in 66.1% [G1], 83.3% [G2], and 76.0% [G3] of samples. Interestingly, the majority of WB-indeterminate results were confirmed by LIA as HTLV-2 in G1 and G2, but not in G3, in which the samples were defined as HTLV-1 or HTLV positives. These results agree with the virus types that circulate in such patients of different regions in Brazil, and emphasize the LIA as the best serological test for confirming HTLV-1 and HTLV-2 infections, independently of being applied in HTLV-monoinfected or HTLV-coinfected individuals.